Aug 05, 2024 8:00am EDT Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
Aug 01, 2024 8:20pm EDT Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
Jun 03, 2024 12:00pm EDT Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
May 30, 2024 4:01pm EDT Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
May 01, 2024 12:00pm EDT Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
Apr 12, 2024 8:00am EDT Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
